Bio Path reported $9.15M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Baxter International USD 3.81B 218M Sep/2026
Bio Path USD 9.15M 468K Mar/2026
Cipla INR 69.77B 366.6M Sep/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.63M 596K Jun/2026
CSL USD 4.61B 207M Dec/2025
Grifols EUR 2.37B 156.97M Dec/2025
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026